Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210130473TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
US 06.05.2021
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17066897 Applicant Silverback Therapeutics, Inc. Inventor Peter R. BAUM

Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.

2.20210128619USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
US 06.05.2021
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17089594 Applicant CELGENE CORPORATION Inventor Timothy CAMPBELL

Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.

3.WO/2021/084104TETRAVALENT ANTIBODY MOLECULES
WO 06.05.2021
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/EP2020/080585 Applicant BIOINVENT INTERNATIONAL AB Inventor MATTSSON, Mikael
Disclosed herein are tetravalent immunoglobulins and F(ab')2 fragments containing two Fv regions each consisting of two variable heavy (VH) domains, two constant light (CL) domains, and either two heavy chain constant regions, or two constant heavy 1 (CH1) domains and a hinge. Also disclosed herein are methods for producing such tetravalent immunoglobulins and F(ab')2 fragments.
4.WO/2021/084494NOVEL PEPTIDES AND USES THEREOF FOR TREATING CANCER
WO 06.05.2021
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/IB2020/060207 Applicant SYMTHERA CANADA LTD. Inventor EZERZER, Chai
Presented herein are cancer peptide agents and uses thereof for treating cancer and/or inhibiting metastasis. Also presented herein are methods of treating cancer, or inhibiting metastasis of cancer in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents to the subject. Also presented herein is a method of treating a cancer in a subject, or inhibiting metastasis of a cancer in a subject that comprises administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents, and administering a chemotherapy or chemotherapeutic agent.
5.WO/2021/083204KERATIN BD-14, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO 06.05.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/CN2020/124365 Applicant INSTITUTE OF MATERIA MEDICA , CHINESE ACADEMY OF MEDICAL SCICENCES Inventor YU, Shishan
Provided are keratin BD-14, a nucleic acid molecule encoding keratin BD-14, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a preparation method for keratin BD-14, a pharmaceutical composition containing keratin BD-14, and an application of said keratin BD-14, nucleic acid molecule, expression vector, host cell, or pharmaceutical composition in preparing antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, blood pressure lowering, anti-inflammatory and antiviral drugs.
6.WO/2021/086159PROTEIN FUSED WITH MOLECULE CAPABLE OF BINDING TO IMMUNE CHECKPOINT MOLECULE AND USE OF SAME
WO 06.05.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/KR2020/015165 Applicant CELLEMEDY CO.,LTD Inventor LEE, Jee Won
The present invention relates to a protein fused with a disease antigen and a use of same. The protein of the present invention is formed via self-assembly of ferritin monomers fused with a disease antigen epitope. The protein of the present invention exhibits excellent binding affinity to a human transferrin receptor, and thus can provide disease antigen epitopes of various kinds and lengths to antigen-presenting cells to induce an immune response to the corresponding antigen.
7.WO/2021/086219LIGHT-GATED PENTAMERIC CHANNEL - A NEW OPTOGENETIC TOOL
WO 06.05.2021
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/RU2019/000776 Applicant FORSCHUNGSZENTRUM JÜLICH, INSTITUTE OF COMPLEX SYSTEMS Inventor BRATANOV, Dmitry Olegovich
The invention relates to newly characterized light-gated pentameric channels such as OLPVRII and their use in medicine, their utility as optogenetic tools, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells expressing said light-gated pentameric channels and their respective uses.
8.WO/2021/086999THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE
WO 06.05.2021
Int.Class A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Appl.No PCT/US2020/057784 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor GONZALEZ, David J.
Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.
9.WO/2021/087044METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA
WO 06.05.2021
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/US2020/057860 Applicant CELGENE CORPORATION Inventor TOWFIC, Fadi, George
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
10.WO/2021/087344THERANOSTICS FOR HYPERTENSION INDUCED MYOCARDIAL MICROBLEEDS
WO 06.05.2021
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/US2020/058335 Applicant CEDARS-SINAI MEDICAL CENTER Inventor DHARMAKUMAR, Rohan
The invention relates to methods of cardiovascular imaging and/or measurement of blood markers for detecting, diagnosing and/or prognosing cardiac or myocardial microbleeds, especially in subject with hypertension and cardiovascular diseases. Treatment methods are also provided for subjects identified, diagnosed, prognosed, or detected with cardiac or myocardial microbleeds. In some embodiments, the subject has hypertension-induced microbleeds, but has not had a myocardial infarction or reperfusion therapy.